[Malignant neuroleptics syndrome].
The neuroleptic malignant syndrome is clinically characterised by the presence of severe muscular rigidity, altered consciousness, hyperthermia and by signs of autonomic dysfunction. A severe form of the syndrome lasting several weeks was observed in a 20-year-old, mentally retarded female patient while under fluphenazine treatment. Cerebrospinal fluid was examined for monoamine metabolites by high-performance liquid chromatography both during the acute and the convalescent phases of the disease. Since the disease carries a considerable mortality, early diagnosis and rapid withdrawal of all neuroleptic medication is of primary importance.
D000328:Adult; D000547:Amantadine / Q000627:therapeutic use; D001418:Baclofen / Q000627:therapeutic use; D002555:Cerebrospinal Fluid / Q000032:analysis; D002853:Chromatography, Liquid; D003072:Cognition Disorders / Q000139:chemically induced; D005260:Female; D005334:Fever / Q000139:chemically induced; D005476:Fluphenazine / Q000009:adverse effects*; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy*; D009127:Muscle Rigidity / Q000139:chemically induced; D013577:Syndrome
D000547:Amantadine; D001418:Baclofen; D005476:Fluphenazine
Malignes Neuroleptika-Syndrom.